FDA Denies Approval for Duchenne Muscular Dystrophy Drug FDA Denies Approval for Duchenne Muscular Dystrophy Drug
The FDA has nixed approval of golodirsen injection for the treatment of Duchenne muscular dystrophy, citing concerns over risk for infusion port infections and possible renal toxicity.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
More News: Brain | Muscular Dystrophy | Neurology | Neurosurgery | Reflex Sympathetic Dystrophy | Toxicology